Condition: Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma · Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
The study evaluated the overall survival (OS) of SHR-A1904 versus investigator-selected treatment in second-line CLDN18.2-positive advanced GC/GEJC patients
This description comes directly from the study's public registry record.
Qi Shi · 86-021-23511999 · shi.qi.qs16@hengrui.com
Liang Hu · 18036618148 · Liang.hu@hengrui.com
Always discuss trial participation with your own doctor first.
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06649292